SAN ANTONIO (September 4, 2024) – Texas Biomedical Research Institute (Texas Biomed) has secured a contract from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID).
The NIH award is part of a multiple award Indefinite Delivery, Indefinite Quantity (IDIQ) contract program. The Base IDIQ contract has a seven-year performance period and supports a portfolio of research services for recurring needs.
“The importance of this is immense and represents years of dedicated work and proven strength in helping develop responses to emerging and re-emerging local and global disease threats,” said Larry Schlesinger, M.D., President/CEO. “Texas Biomed has built a reputation for saving time, money and lives – all of which are critically important to make infectious disease countermeasures available before they are needed, rather than reactively when it’s too late.”
It was secured by Texas Biomed’s Applied Science and Innovation (ASI) unit, which has been significantly expanding contract research, innovation and commercialization at the Institute.
Texas Biomed was awarded three out of the four task areas for delivering preclinical models of infectious diseases supporting NIAID strategic pandemic-preparedness capabilities. Such research provides key insights into ways to better understand, treat and ultimately prevent infectious diseases.
“[These base IDIQ awards] demonstrate Texas Biomed’s ability to compete for important contracts, and further advances our standing nationally and internationally as a premier institution that delivers the quality science necessary to advance therapies and vaccines to market,” said Cory Hallam, Ph.D., Executive Vice President of ASI.
Along with Hallam, co-investigators on the new contract includes Ricardo Carrion, Ph.D., Director of Texas Biomed’s Maximum Containment Contract Research (MCCR) group and Corinna Ross, Ph.D., Director of Texas Biomed’s Southwest National Primate Research Center (SNPRC). Additional Texas Biomed researchers will join the team on specific task area studies as they are awarded.
The NIH/NIAID award enables work developing and bridging animal research study data to humans to provide evidence of therapy and vaccine effectiveness. This is key in infectious disease responses and the development of medical countermeasures when conducting human clinical trials is not feasible
###
About Texas Biomedical Research Institute
Texas Biomed is a nonprofit research institute dedicated to protecting the global community from infectious diseases. Through basic research, preclinical testing and innovative partnerships, we accelerate diagnostics, therapies and vaccines for the world’s deadliest pathogens. Our San Antonio campus hosts high containment laboratories and the Southwest National Primate Research Center. Our scientists collaborate with industry and researchers globally and have helped deliver the first COVID-19 vaccine, the first Ebola treatment and first Hepatitis C therapy. Learn more at txbiomed.org.
This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93024D00022.